Mosunetuzumab Monotherapy Continues to Demonstrate Promising Efficacy and Durable Complete Responses in Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

MLA

Olszewski, Adam J., et al. “Mosunetuzumab Monotherapy Continues to Demonstrate Promising Efficacy and Durable Complete Responses in Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma.” Blood, vol. 140, no. Supplement 1, Nov. 2022, pp. 1778–80. EBSCOhost, https://doi.org/10.1182/blood-2022-157768.

APA

Olszewski, A. J., Avigdor, A., Babu, S., Levi, I., Eradat, H., Abadi, U., Holmes, H., McKinney, M., Woszczyk, D., Giannopoulos, K., Jurczak, W., Dunshee, D., Yang, A., Zhou, M., Qayum, N., Sellam, G., & Horowitz, N. A. (2022). Mosunetuzumab Monotherapy Continues to Demonstrate Promising Efficacy and Durable Complete Responses in Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma. Blood, 140(Supplement 1), 1778–1780. https://doi.org/10.1182/blood-2022-157768

Chicago

Olszewski, Adam J., Abraham Avigdor, Sunil Babu, Itai Levi, Herbert Eradat, Uri Abadi, Houston Holmes, et al. 2022. “Mosunetuzumab Monotherapy Continues to Demonstrate Promising Efficacy and Durable Complete Responses in Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma.” Blood 140 (Supplement 1): 1778–80. doi:10.1182/blood-2022-157768.